VK2735
PMID 41508550 reports 9.1% to 14.7% mean weight loss after 13 weeks across four VK2735 groups (checked: 2026-08-26). Placebo produced a 1.7% loss. The phase 2 trial randomized 176 adults. Viking Therapeutics funded the study.
Among the active groups, 130 of 140 people lost at least 5% of body weight in PMID 41508550. The placebo result was 4 of 34 people.
The five-percent mark was a separate test for each person. It was not the mean change for the group.
A mean joins all measured changes in one group. It does not mean that each person lost the same share.
Some people lost more and some lost less. The responder count shows how many crossed one set mark.
What is VK2735?
VK2735 is a peptide that activates the GIP and GLP-1 receptors (PMID 41508550; checked: 2026-08-26). Viking Therapeutics is developing it for weight management.
The word dual records action at both receptor types. It does not grade the two effects.
The register carries the alias VK-2735. It carries no identifiers block. It therefore gives no UNII, CAS number, or identifier verification date.
A captured GSRS search returned no exact VK2735 result (checked: 2026-08-15). That search absence does not prove that no identifier will ever be assigned.
The page therefore leaves both code fields blank. It does not borrow a code from a related drug.
What did the published phase 2 trial report?
PMID 41508550 was a 13-week randomized, double-blind, placebo-controlled trial (checked: 2026-08-26). It ran at 20 sites in the United States. People with diabetes could not enter. Viking Therapeutics funded the work.
The main test asked how body weight changed from the start to week 13. People were put into a group by chance. They received placebo or one of four active study regimens. The people and study staff did not know the group.
The full study lasted 23 weeks, including the safety follow-up. The treatment part lasted 13 weeks.
| Finding in PMID 41508550 | Result | Funding |
|---|---|---|
| People randomized | 176 | Viking Therapeutics |
| Main efficacy analysis | 174 | Viking Therapeutics |
| Mean weight loss across active groups | 9.1% to 14.7% | Viking Therapeutics |
| Mean weight loss with placebo | 1.7% | Viking Therapeutics |
| Lost at least 5% with VK2735 | 130/140 (93%) | Viking Therapeutics |
| Lost at least 5% with placebo | 4/34 (12%) | Viking Therapeutics |
The study had not reached a weight-loss plateau at week 13. It did not compare VK2735 directly with another medicine.
Thirteen weeks is a short test. It does not show how much weight stayed off in a long trial. It also does not show a direct result against another peptide.
The low end of the active range was 9.1% in PMID 41508550. The high end was 14.7%. Placebo lost 1.7% on average.
Each active group beat placebo in the main test. The paper reports a dose response across the four groups.
What safety findings did the phase 2 trial record?
The safety analysis in PMID 41508550 included 175 people. Viking Therapeutics funded the study.
| Safety finding in PMID 41508550 | Result |
|---|---|
| At least one event of any type | 142/175 (81.1%) |
| At least one drug-related event | 120/175 (68.6%) |
| Maximum severity mild | 71/175 (40.6%) |
| Maximum severity moderate | 41/175 (23.4%) |
| Maximum severity severe | 8/175 (4.6%) |
| Life-threatening event | 0 |
| Nausea linked to study drug | 64/175 (36.6%) |
| Constipation linked to study drug | 37/175 (21.1%) |
| Vomiting linked to study drug | 22/175 (12.6%) |
Sixteen of 175 people had an event that led them to stop the study drug in PMID 41508550. Eight of 175 people had twelve serious events. Investigators judged ten of those twelve unrelated to the study drug.
One person had atrial fibrillation and dehydration that investigators considered related. The person left the study.
One person died after head trauma from a fall. Investigators judged the death unrelated to VK2735.
These are counts from the whole safety set. They do not predict what one person will feel. The study team linked each event to the drug or judged it unrelated.
The denominator was the same set of 175 people for each row. A person could have more than one kind of event.
Most drug-related events were mild or moderate in PMID 41508550. Eight people had a severe event. No person had a life-threatening event.
Nausea was the most common linked event. Constipation and vomiting came next in the paper.
Gut-related events were most common early in the trial. Their reported rate fell with time after the dose steps.
The paper says Viking Therapeutics supported the study. It says the authors were principal site investigators at paid sites or Viking employees.
What trials are running now?
The current phase 3 records have no posted results (checked: 2026-08-26).
| Trial record | Status | Planned enrollment | Sponsor |
|---|---|---|---|
| NCT07104500 | Active, not recruiting | 4,500 estimated | Viking Therapeutics |
| NCT07104383 | Active, not recruiting | 1,100 estimated | Viking Therapeutics |
These enrollment numbers are plans, not completed populations. Neither record supplies an outcome.
A trial can be active before it has a result. A planned group size is not proof that this many people finished.
Both phase 3 records still list the group size as an estimate. The records do not yet give measured weight or safety outcomes.
The larger record plans a broad weight study. The smaller record plans a study in people with type 2 diabetes.
Both are tests of the drug in people. Neither is a posted result yet.
What are the evidence and regulatory status?
Evidence tier: B (checked: 2026-08-26). A randomized human phase 2 result is published. Phase 3 trials are underway.
EU register status: unclear (checked: 2026-08-26). The register does not establish a current national or central EU marketing authorization. Trial activity is not marketing authorization.
An unclear field is not a refusal or an approval. It means the source set does not settle the answer.
The phase 2 paper proves that a human trial took place. It does not prove that a regulator approved the drug for sale.
Germany and Sweden also remain unclear in the register. This page does not turn those fields into a legal verdict.
What does grey-market vial testing show?
The 2026 vial-study text lists fourteen compounds (checked: 2026-08-26). VK2735 is not one of them.
The paper gives no VK2735 report count. It gives no amount or identity result. It gives no purity, endotoxin, or sterility result for VK2735.
The absence is about this paper. It is not a claim about every vial in the market.
The paper tested other named compounds. It cannot supply a result for a compound that was not in its list.
When was VK2735 first observed outside research?
No sound first grey-market month is known (checked: 2026-08-26). The register keeps first_observed: null rather than estimating a date.
What do users report?
The reviewed forum inventory contains no opened VK2735 thread (checked: 2026-08-26). This page therefore quotes no account and makes no claim about a group.
This page adds a quote only after its thread can be opened and checked. A later opened thread can become its own evidence.